PIN-A1

PIN-A1 is a potent and selective molecular glue degrader (MGD) targeting Casein Kinase 1 alpha (CK1α). Developed by Pin Therapeutics, it functions by hijacking the Cereblon (CRBN) E3 ligase to form a ternary complex, leading to the selective proteasomal degradation of CK1α. CK1α is an isoform of casein kinase 1 that promotes tumor growth by enhancing the negative effects of MDM2 and MDMX on the p53 tumor suppressor. By degrading CK1α, PIN-A1 stabilizes and activates the p53 pathway, inducing apoptosis in cancer cells, particularly those with wild-type TP53. Preclinical studies have demonstrated robust antitumor activity in acute myeloid leukemia (AML) models and solid tumors, both as a monotherapy and in combination with other targeted agents, while maintaining a favorable safety profile with minimal impact on healthy peripheral blood mononuclear cells (PBMCs).